Search research articles
Contact Us
Filters
Showing results (311-320 of 419) with videos related to
Page
of 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2026
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer
Francesca Jackson-Spence, James Larkin, Poulam Patel, et al.
Cell Reports. Medicine
|
February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
James Larkin, Richard Marais, Nuria Porta, et al.
Journal for Immunotherapy of Cancer
|
July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
James L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
The Lancet. Oncology
|
February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrity
Paul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
The Lancet. Oncology
|
July 24, 2020
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
Amit Sud, Bethany Torr, Michael E Jones, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Melanoma Research
|
September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Jessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
The Journal of Pathology
|
November 19, 2016
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
Victoria L Bridgeman, Peter B Vermeulen, Shane Foo, et al.
Page
of 42
Search research articles
Search
Showing results (311-320 of 419) with videos related to
Sort By:
Page
of 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2026
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer
Francesca Jackson-Spence, James Larkin, Poulam Patel, et al.
Cell Reports. Medicine
|
February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial
James Larkin, Richard Marais, Nuria Porta, et al.
Journal for Immunotherapy of Cancer
|
July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
James L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations
Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
The Lancet. Oncology
|
February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrity
Paul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
The Lancet. Oncology
|
August 3, 2016
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A Ascierto, Grant A McArthur, Brigitte Dréno, et al.
The Lancet. Oncology
|
July 24, 2020
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
Amit Sud, Bethany Torr, Michael E Jones, et al.
The New England Journal of Medicine
|
June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V Long, Axel Hauschild, Mario Santinami, et al.
Melanoma Research
|
September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Jessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
The Journal of Pathology
|
November 19, 2016
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
Victoria L Bridgeman, Peter B Vermeulen, Shane Foo, et al.
Page
of 42